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A B S T R A C T   
Alzheimer’s disease (AD) is classified pathologically as a progressive neurological disorder associated with 
memory decline. The study was designed to assess the underlying molecular signaling involved in the neuro-
protective effect of the 2-(hydroxyl-(2-nitrophenyl)methyl)cyclopentanone (2NCP) as a novel therapeutic agent 
for AD. In this connection, in vitro cholinesterases inhibitory and antioxidant activities were investigated. In vivo 
studies were carried out on a well-known 5xFAD mice model in different behavioural models such as light/dark 
box,balance beam, rotarod, elevated plus maze (EPM),novel object recognition (NOR), paddling Y-maze, and 
Morris water maze (MWM) tests. Hippocampus (HC) and frontal cortex (FC) homogenates were examined for 
acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities, 1,1-diphenyl-2-picrylhydrazyl (DPPH) 
free radicals, glutathione S-transferase (GST), glutathione (GSH), and catalase. Further, we examined the 
expression of inflammatory cytokines and Nrf2 in the HC and FC through RT-PCR. Computational studies were 
conducted to predict the binding mode of the 2NCP with target sites of nuclear factor-κB (NF-κB) and cholin-
esterases. The findings of in vitro assays revealed that the IC50 values of the 2NCP against AChE and BChE were 17 
and 23 µg/ml respectively. DPPH antioxidant assay displayed an IC50 value for the 2NCP was 62 µg/ml. Whereas, 
theex vivo study depicted that the activities of AChE and BChEwere significantly reduced. Moreover, free radicals 
load, GSH level, catalase and GST activities were significantly declined. Furthermore, in vivostudies showed that 
the 2NCP treated animals exhibited gradual memory improvement and improved motor functions. RT-PCR study 
revealed that mRNA levels of the inflammatory mediators (IL-1β, IL-6, TNF-α) were significantly reduced, while 
the expression of antioxidant Nrf2 was significantly increased.The molecular docking studies further confirmed 
that the 2NCP showed excellent binding affinities for NF-κB and cholinesterases. Taken together, the 2NCP 
improves spatial memory and learning, short- and long-term memory,markedly inhibits cholinesterases, reduced 
neuroinflammation, and mitigated oxidative stress in the 5xFAD mice; hence the 2NCP may be a potential 
candidate for the management of AD.   
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1. Introduction 
Alzheimer’s disease (AD) is one of the most prevalent and progres-
sive dementing disorder in the elderly and affects those brain areas that 
control memory, thoughts, language, and adversely affects the quality of 
life of the patients[1]. Different etiological pathways have been reported 
to detect AD. These pathways include the level of cholinesterases and 
beta-amyloid (Aβ) proteins, cerebral blood flow, neurotransmitter fluc-
tuations, neuroinflammation, and the development of oxidative stress 
[2–3]. In AD, impairment of cholinergic functions in brain areas such as 
the hippocampus and neocortex occur which are dealing with memory, 
behavior, learning, and emotional responses. Acetylcholine (ACh) level 
decreases in the brain of AD individuals. Acetylcholinesterase (AChE) 
and butyrylcholinesterase (BChE) enzymes are responsible for the hy-
drolysis of acetylcholine[4]. Hence, inhibition of these enzymes has 
been reported as critical targets in the treatment of AD, leading to an 
increase in the level of ACh in brain areas [5]. Oxidative stress plays a 
key role in the pathogenesis of AD, characterized by an imbalance be-
tween the free radicals production rate and the anti-oxidant defense 
system of the body [6–7]. Free radicals are associated with Alzheimer’s 
disease, cause neuronal damage and death [8–9]. The inflammatory 
activity of macrophages, neutrophils, and by-products of mitochondrial 
electron transport chain reactions are sources of free radicals. Reactive 
oxygen species (ROS) such as hydrogen peroxide, superoxide anion, and 
hydroxyl ions produced during normal metabolic reactions as a by- 
product. These ROS adversely affect the cell membrane; decrease the 
fluidity of the membrane, and causing loss of structural and functional 
capability of the membrane. Such changes have been observed in many 
diseases including AD [10–11]. Antioxidants scavenge free radicals by 
neutralizing their activities [12–13]. Nuclear factor-erythroid 2 related 
factor 2 (Nrf2) is a transcription factor that causes protection against 
free radicals by regulating the antioxidant/detoxification genes 
expression, that can alleviate oxidative stress neurotoxicity [14]. 
Chronic neuroinflammationhas been described that it causes loss of 
neurons in neurodegenerative diseases including AD [15–17]. Literature 
studies have revealed that excessive or chronic inflammation mediated 
by activated microglia, pro-inflammatory cytokines, and several oxida-
tive stress entities, such as glutamate, ROS, and nitric oxide (NO) are 
deleterious to AD brain tissues. Pro-inflammatory cytokines such as IL- 
1β, IL-6, and TNF-α, released by over-activated microglia, activate the 
surrounding astrocytes, which may act on neurons directly to induce 
synaptic dysfunction or apoptosis [18–19]. During progressive neuro-
inflammation, intracellular signaling cascades including nuclear factor- 
κB (NF-κB) become activated which induces the expression of various 
inflammatory cytokines[20].The over-expressed cytokines initiate an 
over activated response to inflammation which may lead to chronic 
neuronal damage [21–22]. Unfortunately, efficient therapy for AD is still 
lacking, hence, the search for more effective synthetic anti-AD com-
pounds with anti-cholinesterase, anti-oxidant, and anti-inflammatory 
properties is need of the day. 
Effective pharmacotherapeutic management of AD will reduce the 
burden on the health care system of the country, both in terms of cost 
and health. Currently, for the treatment of AD, five drugs are used in 
clinical setup, containing four acetylcholinesterase inhibitors (galanth-
amine, rivastigmine, tacrine, and donepezil) and NMDA receptor 
antagonist, memantine. These drugs provide symptomatic relief to AD 
patients [23] . 
The β-hydroxy ketone derivative; 4-([1,1′-biphenyl]-3-yl)-1-(benzyl 
(2-(2-methoxyphenoxy)ethyl)amino)-4-hydroxybutan-2-one inhibit 
acetylcholinesterase, confirmed by docking and in vitro studies [24]. 
Ketone bodies have the potential to ameliorate AD, amyotrophic lateral 
sclerosis, stroke, traumatic brain injury, and Parkinson’s disease 
[25–26]. β-hydroxy ketone derivatives; 2-(hydroxyl-3-nitrophenyl) 
methyl)cyclopentanone and 2-(hydroxyl-(4-nitrophenyl)methyl)cyclo-
pentanone were tested in our lab, finding of these studies showed sig-
nificant inhibition of cholinesterases, oxidative stress, reduced plaques 
in the HC and FC, and improved memory in 5xFAD mice [27–28]. There 
is no effective drug in the market to treat AD, hence, across the globe 
research is going on to find out therapeutically effective drugs for this 
disease. Also, there are many limitations in currently available AChE 
inhibitors like cost and effectiveness, etc[29]. Moreover, it has been 
reported that the ketone bodies, aldol adducts, and their derivatives 
have the potential to relieve neurodegenerative disorders (Wood et al. 
2018), in the same perspective we have selected 2-(hydroxyl-(2-nitro-
phenyl)methyl)cyclopentanone (2NCP) (Fig. 1) as a possible potential 
candidate against AD. Indeed, the real promise of metabolic/ketogenic 
approaches is that by altering cellular energy, oxidative stress, and 
inflammation, ketogenic (and possible 2NCP) have the potential to do 
more than provide symptomatic relief but also have the potential to alter 
disease trajectory. The 2NCP has a nitrophenyl group, and literature 
studies revealed that compounds containing nitrophenyl groups have 
the potential to inhibit AChE, BChE, monoamine oxidase-B (MAO-B), 
and relieve oxidative stress [30]. Whereas, the nitrobenzaldehyde de-
rivatives exhibited antioxidant activity due to the nitro group attached 
to the benzene ring [31–32]. The 2NCPwas synthesized by the previ-
ously reported method [33–34]. 
In this regard, the neuroprotective potential of the 2NCP was 
assessed in the 5xFAD mice along with short- and long-term memory, 
spatial memory, and anxiety. Furthermore, attempts were made to 
investigate the potential mechanisms of the 2NCP neuroprotective ef-
fect, for this purpose, the level/activities of the AChE and BChE, catalase, 
GST, GSH, inflammatory mediators (IL-1β, IL-6, TNF-α), and Nrf2 
wereevaluated in the hippocampus and frontal cortex. Moreover, the 
computational study was carried out to predict the binding mode of the 
2NCP with cholinesterases and NF-κB. 
2. Materials & methods 
2.1. Materials 
Acetylcholinesterase (Electric eel), butyrylcholinesterase (equine 
serum), acetylthiocholine iodide, butyrylthio-choline Iodide, 5,5-dithio- 
bis-nitrobenzoic acid (DTNB), galanthaminehydrobromide, 1,1- 
diphenyl-2-picrylhydrazyl (DPPH), hydrogen peroxide (H2O2), tri-
chloroacetic acid (TCA), sodium citrate, glutathione-S-transferase 
(GST), l-chloro-2, 4-dinitrobenzene, EDTA, boric acid, agarose, and 
ethidium bromide were obtained from Sigma-Aldrich USA. DNA 
extraction kit (Novel Genomic DNA Mini Kit), TRI-reagent (Bioshop, 
Canada), Tris (Scharlu Spain), cDNA synthesis kit (ABM, Canada), PCR 
primers (Macrogen Korea) were used. PCR Master Mix and Taq poly-
merase were obtained from Thermo Fisher Scientific US. DNA Ladder, 
dNTPs, magnesium chloride were purchased from Invitrogen US, while 
ethanol, isopropanol, and chloroform were obtained from Merck 
Germany. 
2.2. In vitro assays 
2.2.1. Acetylcholinesterase and butyrylcholinesterase inhibition assays 
Cholinesterases inhibition assay of the 2NCP was carried out 
following standard Ellman’s assay. Acetylthiocholine iodide and butyr-
ylthiocholine iodide were used as substrates. Degradation of these sub-
strates leads to the formation of 5-thio-2-nitrobenzoate, which forms a 
Fig. 1. Chemical structure of the 2-(hydroxy-(2-nitrophenyl)methyl) 
cyclopentanone. 
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yellow color complex with DTNB, which was assayed through micro-
plate reader at 412 nm wavelength [35]. 
The rate of absorbance (V = ΔAB/Δt) showed the %-enzyme activity 
and inhibition by the test and control samples and was calculated as 
follows, 
%-Enzyme inhibition = 100− enzyme activity (%) 
%-Enzyme activity = 100× V/Vmax 
Vmax shows the maximum enzyme activity in the absence of 
inhibitory agent. 
2.2.2. DPPH scavenging assay 
The DPPH radical assay was conducted following reported protocol 
with slight modifications [36]. Following this method, 0.024 % solution 
of DPPH and 0.1 % stock solutions of control and test drugs were pre-
pared in methanol. The stock solution of the test drugs was further 
diluted to different concentrations, and 0.1 ml of these diluted solutions 
was added to the DPPH solution in microplate-reader (96 wells) and the 
absorbance was measured at 517 nm. 
2.3. In vivo activities 
2.3.1. Animals 
In vivo studies were conducted in the 5xFAD mouse model of Alz-
heimer’s disease, sub-strain of Jax strain006554, MMRRC034840 
B6SJL-Tg (APPSwFILon, PSEN1* M146L*L286V) 6799Vas/Mm ob-
tained from Jackson laboratory US. A letter of permission has been 
obtained from Jackson laboratory, to utilize these animals for research 
purposes. 5xFAD mice of either sex (age: 5–6 months) were used as a 
disease group and wild-type mice littermates were used as a control 
group. Animals were bred and kept at 22 ± 2 ◦C with 12/12 h light/dark 
cycle in the animal house at the Department of Pharmacy, University of 
Peshawar, Pakistan. 
2.3.2. Research ethical approval 
Departmental research ethical committee of the University of 
Peshawar has approved all experimental procedures on animals vides a 
reference number 12/EC-17/Pharm, dated. 24/05/2017. All experi-
ments were carried out according to the Animals’ Scientific Procedures 
Act, 1986. 
2.3.3. Animal grouping and route of drug administration 
In this study, animals were divided into six groups (n = 10). 
Group I: Wild type (WT) mice 
Group II: 5xFAD transgenic mice 
Group III: 5xFAD-galanthamine (8 mg/kg, i.p) 
Group IV: 5xFAD − 2NCP (10 mg/kg i.p) 
Group V: 5xFAD − 2NCP (20 mg/kg i.p) 
Group VI: 5xFAD − 2NCP (40 mg/kg i.p) 
Galanthamine and 2NCP were dissolving in vehicle containing 
DMSO, Tween-80, and normal saline in a ratio of 5:2:93. Animals were 
treated with vehicle/galanthamine/2NCP for 28 days. 
2.3.4. Genotyping of transgenic mice 
The methodology of genotyping specified by Jackson lab U.S for 
strain transgenic mice was followed with slight modifications [27]. DNA 
extraction was carried out using a DNA extraction kit following the 
manufacturer’s protocol. Two sets of primers were used in genotyping: 
Internal positive control; F, 5′-CTAGGCCACAGAATTGAAAGATCT- 
3′, 
R, 5′-GTAGGTGGAAATTCTAGCATCATCC-3′ and Transgene F, 5′- 
AGGACTGACCACTCGACCAG-3′, R, 5′-CGGGGGTCTAGTTCTGCAT-3′. 
The annealing temperature was 55 ◦C for 60 sec. PCR products were 
identified through gel electrophoresis; amplified products were visual-
ized using a UV trans-illuminator. 
2.3.5. Light/Dark box (LD) test 
The light dark box (LD) test is commonly used to evaluate the anxiety 
status of rodents. The LD box consisted of two compartments; light and 
dark compartments, with an opening between two compartments. The 
mouse was placed in the light compartment and allowed freely to 
explore the apparatus for 5 min, the time latency to enter the dark 
compartment and the time spent in the light compartment were 
observed [37–38]. 
2.3.6. Balance beam test 
The balance beam is made up of a large wood/tube lined with soft 
foam to minimize animal injuries. The starting side was luminous while 
the ending side was darker. Animals were trained one day before 
starting the test trial to reduce neophobia. Animals were administered 
respective drugs and 1 h after drug administration; the animal was 
placed at the luminous ending and allowed to cross the beam. The time 
of crossing the beam was recorded [39]. 
2.3.7. Rotarod test 
Rotarod test is used to assess the motor coordination deficits [40]. 
Animals were trained for two days, four trials each day. Each mouse was 
placed on the accelerating rod (4–40 rpm) for 5 min. On the next day 
after training trials, test trials were carried out and the falling latency 
time was recorded. 
2.3.8. Elevated plus maze (EPM) 
Elevated plus maze is a plus-shaped apparatus consisting of two open 
and two closed arms lying at a right angle to each other with a central 
platform. The time taken by mice to enter from the open-arm into the 
close arm is transfer latency time, which was noted. In-order to habit-
uate the mice with the maze, mice were trained one day before the 
commencement of the test, each animal was kept at one end of the open 
arms and allowed to enter to the close arms, after 10 s stay in close arm 
returned to the home cage. The animal failed to enter into the close arm 
within 120 s, manually guided to enter into the close arm. The above 
procedure was repeated after 24 h to examine the withholding of 
memory [28]. 
2.3.9. Novel object recognition (NOR) test 
The NOR test is commonly used to assess the learning and memory 
[41]. This test was performed in the open field apparatus as described 
for open field test following previously reported method [42]. Each 
mouse was habituated to the apparatus by placing in the empty box 
without any object for 10 min. Mice were trained for 5 min after 
habituation phase by placing in the apparatus containing two similar 
objects. Each animal was tested for the assessment of short term and 
long term memory at 2 hr and 24 hr after the training trial, the animal 
was placed in the box and allowed to explore the apparatus for 5 min. 
During the test trial, one of the objects was replaced with a novel object 
having different shape. Also one of the objects was replaced with 
another new object during long term memory testing carried out 24 hr 
after the training trial. Exploration was defined as touching or sniffing 
the object or head orienting towards the object. The time that the mice 
spent exploring each object during both test trials was recorded and the 
discrimination index was calculated as; Discrimination index (DI) =
time of exploring the novel object/total time of exploration × 100% 
2.3.10. Y-Maze (Paddling) test 
Animals of each group were trained for three days with 3 trials each 
day, one hour apart from each other. The animal was placed in one of the 
close arms ends at the beginning of each trial. The arms selection was 
made with semi-random series of the starting position and three suc-
cessive trails were performed at the same position. The time duration for 
each trial was 60 s and the mice that failed to find the exit hole within 60 
s were guided manually to the open end via a transparent slide. In the 
test trial, animals were subjected to the Y-Maze apparatus for five days 
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and escape latency time was recorded each day. Spontaneous alterna-
tion behavior (SAB) was observed on day 5 of the test trials by placing 
each mouse at the center of the Y-Maze apparatus and allowed to move 
freely through the apparatus for 3 sessions (each session of eight min). 
The numbers of arm-entries were recorded [39]. 





× 100  
2.3.11. Morris water maze (MWM) 
The effect of the 2NCP on the spatial learning and memory of the 
transgenic 5xFAD mice was investigated through the MWM apparatus 
containing opaque water maintained at 22–23 ◦C, according to the re-
ported method with minor modification [43–44]. The maze comprises 
four quadrants with a hidden platform set 1 cm below the water surface 
in one of these quadrants. All animals were trained for 5 days continu-
ously (4 trials/day). The escape latency time in seconds to find the 
submerged platform was observed. The mice which failed to find out the 
hidden-platform in one minute were guided manually and allowed to 
stay on the platform for 10 s. After training, the animals were tested for 
memory retention in the probe trial on day 6. The probe trial was carried 
out without a platform for one minute. The time duration spent by mice 
in the target quadrant and the number of platform area crossings were 
noted. An overhead camera was used for recording the experimental 
activities. 
2.4. Ex vivo assays 
2.4.1. Evaluation of cholinesterase inhibition in the hippocampus and 
frontal cortex 
This assay was carried out following standard protocol. All animals 
of each group were killed by decapitation at the end of behavioral ex-
periments under ether anesthesia. In ice-cold 0.1 M phosphate saline 
buffers (pH 8.0), HC and FC were dissected and homogenized, the su-
pernatant was used for the AChE and BChE assay [35,45]. Thiocholine 
and acetate thiocholine form after degradation of acetylcholine and 
butyrylcholine, which combined with DNTB and produced a yellow 
complex, this complex was assayed by absorbance at 412 nm in a 
microplate reader [46]. 
2.4.2. Glutathione S-transferase (GST), glutathione (GSH) and catalase 
assay 
The activities or level of catalase, GST, and GSH in the hippocampus 
and frontal cortex were determined following Ellman’s method. Hip-
pocampal and frontal cortex tissues were homogenized and centrifuged 
at speed of 1000 × g at 4 ◦C for 15 min, the supernatant was used in this 
assay. The enzymes (GST and catalase) activities and GSH level were 
determined by observing the variation in absorbance via microplate 
reader at specific wavelengths (240, 340, and 420 nm) [47–48]. 
2.4.3. DPPH scavenging assay of the hippocampus and frontal cortex 
The DPPH free radical scavenging activity was carried out following 
the previously reported method [49]. The hippocampus and frontal 
cortex tissues of all animals were homogenized in 1 ml methanol (0.1 
mg/ml) with succeeding addition of 400 µl of DPPH solution (0.1 mM). 
These solutions were maintained at 37 ◦C for 30 min and absorbance 
was measured using a microplate-reader at 517 nm. The inhibition in 






Where AB denotes absorbance, c denotes to control and s indicate 
sample. 
2.5. Reverse transcriptase-PCR (RT-PCR) 
Total RNA was extracted from mice hippocampus and frontal cortex 
according to the manufacturer’s protocol using TRI-reagent and purity 
of total RNA was determined using a UV spectrophotometer. Total RNA 
was transcribed to cDNA using a cDNA synthesis kit. The expression of 
targeted genes was determined. Sequences of targeted genes are; 
IL-1β; forward 5′-AGAAGCTTCCACCAATACTC-3′, reverse 5′- 
AGCACCTAGTTGTAAGGAAG-3′
IL-6; forward 5′-GCCCTTCAGGAACAGCTATGA-3′, reverse 5′- 
TGTCAACAACATCAGTCCCAAGA3′
TNF-α; forward 5′-CTTCTCCTTCCTGATCGTGG-3′, reverse 5′- 
GCTGGTTATCTCTCAGCTCCA3′
Nrf2; forward 5′-CCTCGCTGGAAAAAGAAGTG-3′, reverse 5′-GGA-
GAGGATGCTGCTGAAAG-3 
GAPDH; forward, 5′-TGCACCACCAACTGCTTAGC-3′, reverse 5′- 
GGCATGGACTGTGGTCATGAG3′
GAPDH was used as a housekeeping gene. Amplified products were 
separated using 1.5% agarose gel electrophoresis and visualized by UV 
trans-illuminator. The annealing temperature of IL-1β, Nrf2, and GAPDH 
was 55 ◦C, 60 ◦C of IL-6, and 62 ◦C of TNF-α. The expression level in the 
arbitrary unit was calculated [27,50]. 
2.6. Computational studies 
2.6.1. Molecular docking study cholinesterases 
Molecular docking studies were conducted as per established pro-
tocols to predict the potential interactions of 2NCP with target sites of 
acetylcholinesterase and butyrylcholinesterase[39]. The 3D crystal 
structures of the protein complexes of cholinesteraseswere achieved 
from Protein Data Bank (PDB id 1ACl & 1POI). The edited crystal 
structure was imported into MOE after the removal of water molecules. 
Hydrogen atoms were added to the structure followed by minimizing 
their energy using MOPAC 7.0. The model was subjected to a systematic 
conformational search at default parameters with the RMS gradient of 
0.0001 kcal/mol using Site Finder. The active site of both enzymes was 
selected by the site finder tool of MOE. Root mean square deviation 
(RMSD) values were used to compare the ligand between the predicted 
and its corresponding crystal structure. The lowest energy minimized 
pose was used for further analysis. The 2NCP was docked following the 
same procedure. The resulting ligand-enzyme complex model was then 
used for binding interactions and binding pattern analysis. 
2.6.2. Molecular docking study withNF-κB 
The most appropriate drug target for the compound was selected 
from the KEGG database (https://www.genome.jp/kegg). The pathway 
of Alzheimer’s disease (HSA05010) showed that NF-κB regulates the 
production of TNF-α, IL-1, and IL-6. Therefore compound was docked at 
the binding site of NF-κB. The three-dimensional structure of NF-κB was 
taken from RCSB Protein Data Bank (https://www.rcsb.org/) with PDB 
ID: INFK [51]. The DNA binding residues were deduced and the com-
pound was docked at the DNA binding site of NF-κB. Docking was per-
formed on Molecular Operating Environment (MOE version 2009.14). 
The 3D-structure of the compound was built on MOE and MMFF-94x 
force field was applied to calculate the charges on the ligand. Simi-
larly, hydrogen atoms and partial charges were applied to protein 
structures using the MMFF94x force field. The 2NCP was docked within 
protein using the Triangle Matcher docking method and London dG 
scoring function of MOE. The best docked complex was selected on the 
basis of good interactions and docking score. 
2.7. Statistical analysis 
The in vitro (DPPH, AChE, BChE), ex vivo (AChE, BChE, GST, GSH, 
catalase, DPPH), and elevated plus maze, novel object recognition, 
spontaneous alternation behavior tests data were analyzed by Tukey’s 
R. Ullah et al.                                                                                                                                                                                                                                   
International Immunopharmacology 100 (2021) 108083
5
post hoc test. The light/dark box,balance beam,rotarod, time in the 
target quadrant and the target quadrant crossings (MWM), and RT-PCR 
tests datawere analyzed with one-way ANOVA followed by Dunnett post 
hoc test. The data of the time latency in the MWM and Y maze were 
analyzed by two-way ANOVA followed by Bonferroni test. The IC50 
values were determined by nonlinear regression usingthe GraphPad 
Prism 5. Values were considered statistically different at p < 0.05. The 
results were expressed as mean ± S.E.M. 
3. Results 
3.1. In vitro assays 
3.1.1. Inhibition of cholinesterases by 2NCP 
The acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) 
are enzymes of the brain cholinergic system responsible for the hydro-
lysis of the neurotransmitter acetylcholine. The brain levels of these 
enzymes show a progressive increase in AD [52]. The results of the in 
vitro assay of the 2NCP against AChE and BChEare shown in Table 1. The 
compound 2NCP has concentration dependant inhibitory properties 
against AChEand BChE. Inhibition of these enzymes was observed as 4 
and 10 % at a concentration of 7.8 µg/ml, whereas it was 83 and 85 % at 
a concentration of 1000μ g/ml. The IC50 values were determined against 
AChE and BChE which were 17 and 23 µg/ml respectively. Similarly, 
galanthamine exhibited AChE and BChE inhibition which was 11 and 16 
% at 7.8 µg/ml concentration, whereas it was 89 and 91 % at 1000 µg/ml 
with IC50 values of 13 and 14 µg/ml. Inhibition of AChE by the 2NCP was 
significant at a concentration of 31.25μ g/ml (*p < 0.05). The BChE 
inhibited by the 2NCP significantly at concentration of 31.25 and 62.5 
µg/ml (p < 0.05, p < 0.001). 
3.1.2. DPPH radicals scavenging activity of 2NCP 
The free radicals and reactive oxygen species (ROS) play an impor-
tant role in the development of oxidative stress that can lead to several 
diseases including AD.Antioxidants are exogenous or endogenous mol-
ecules that alleviate any form of oxidative stress [53].The antioxidant 
potential of the 2NCP was screened by the in vitro DPPH assay. This assay 
revealed concentration dependant anti-oxidant ability of the 2NCP (IC50 
= 62 µg/ml) as shown in Table 2. Maximum inhibition was observed at 
the concentration of 1000 µg/ml. 
3.2. In vivo assays 
3.2.1. Effect of 2NCP in the light/dark (LD) box test 
The light–dark (LD) box test is used to assess the unconditioned 
anxiety responses in rodents [54].The time latency of animal to enter 
into the dark compartment from the light compartment and the time 
spent in the light compartment were investigated in the LD box test. 
However, there was no obvious difference among all groups (Fig. 2. 
A&B). 
3.2.2. Effect of 2NCP in the balance beam test 
This test is used for the assessment of balance and motor coordina-
tion deficit in rodents. In the balance beam test the animals in all groups 
were crossed the beam successfully in same time, showed no defects in 
the balance of animals (Fig. 2.C). 
3.2.3. Effect of 2NCP in the rotarod test 
The transgenic 5xFAD and non-transgenic wild type (WT) mice fell 
from the rod at the same time, displayed no defects in the motor- 
coordination and balance of animals. Similarly, the 2NCP and galanth-
amine treated 5xFAD mice showed the same latency time of falling 
(Fig. 2.D). 
3.2.4. Effect of the 2NCP in the elevated plus maze (EPM) test 
The elevated plus maze (EPM) test is used to measure memory 
related behavior in rodents. The time in which the mice move from the 
open arm into the enclose arm is known as transfer latency (TL), which is 
used as an index of learning and memory in mice and rats[55].The ef-
fects of the 2NCP on learning, memory, and the response to a novel 
situation were assessed by observing their relative-exploration of two 
different environments. The transfer latencies in acquisition (day 1) and 
retention (day 2) trials were noted for all mice. The 5xFAD mice 
exhibited more transfer latency time in acquisition and retention trials 
as compared to the WT mice (p < 0.001). Whereas, the 5xFAD mice 
treated with the 2NCP (10 mg/kg) transferred in less time from open 
into the close arm as compared to the 5xFAD mice (p < 0.05) in the 
retention trial. The mice treated with the 2NCP at the dose of 20 mg/kg 
exhibited a decrease in transfer latency in both trails as compared to the 
vehicle-treated 5xFAD mice (p < 0.01, p < 0.001). The galanthamine 
(GLN) and 2NCP (40 mg/kg) showed a more significant reduction in 
transfer latency time in both trails (p < 0.001) (Fig. 3.A). 
Table 1 


















2NCP 07.8 4 ± 2 17  10 ± 1 23  
15.6 27 ± 6   22 ± 3   
31.25 44 ± 3*   46 ± 4*   
62.5 55 ± 2   53 ± 2**   
125 65 ± 4   64 ± 1   
250 72 ± 3   70 ± 4   
500 77 ± 3   78 ± 3   
1000 83 ± 3   85 ± 4  
Galanthamine 07.8 11 ± 2 13  16 ± 2 14  
15.6 36 ± 2   32 ± 6   
31.25 54 ± 3   57 ± 2   
62.5 62 ± 2   70 ± 5   
125 71 ± 2   75 ± 3   
250 77 ± 3   80 ± 4   
500 85 ± 2   88 ± 3   
1000 89 ± 4   91 ± 2  
Values shown in table are expressed as means ± SEM. p < 0.05 was considered 
significant statistically. *p < 0.05, **p < 0.01, shows different significant values 
of the 2NCP as compared to the galanthamine treatment at the same 
concentration. 
Table 2 
Results of the 2-(hydroxy-(2-nitrophenyl)methyl)cyclopetanone (2NCP) in the in 
vitro DPPH radicals scavenging assay.  
Samples  DPPH free radical scavenging   
Concentration (μg/ml)  % Scavenging activity IC50 µg/ ml 
2NCP  07.8 7 ± 1* 62   
15.6 13 ± 2   
31.25 27 ± 3*   
62.5 45 ± 4*   
125 57 ± 2*   
250 70 ± 4   
500 80 ± 2   
1000 84 ± 2 
Ascorbic acid  07.8 16 ± 1 47   
15.6 21 ± 2   
31.25 36 ± 3   
62.5 56 ± 2   
125 67 ± 2   
250 69 ± 3   
500 80 ± 2   
1000 89 ± 2 
Values shown in table are expressed as means ± SEM. P < 0.05 was considered 
significant statistically. *p < 0.05 shows different significant values of the 2NCP 
as compared to the standard at same concentration. 
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3.2.5. Effect of 2NCP in the novel object recognition test 
Short and long term memory of mice was investigated by novel ob-
ject recognition test. The 5xFAD mice showed robust cognitive impair-
ment as compared to the wild type mice, indicated by a significant 
decrease in the discrimination index (p < 0.001). The 2NCP (10–40 mg/ 
kg) treated mice displayed a significant recovery of cognitive function 
depicted by increased discrimination index in both memory tests (2-and 
24-h) (p < 0.05, p < 0.01, p < 0.001) (Fig. 3.B). 
3.2.6. Effect of 2NCP in the Y-Maze (Paddling) test 
Paddling Y-maze was performed for the analysis of spatial learning 
and memory [28].In the paddling Y-Maze test, escape latency time was 
determined for each group of animals for five consecutive days. The 
results showed that the 5xFAD group exhibited an increase in the latency 
time as compared to the WT-group (p < 0.001). The 2NCP at a low dose 
of 10 mg/kg showed a significant decrease in the latency time on days 4 
and 5 (p < 0.05), at dose of 20 mg/kg caused significant decrease in the 
latency time on days 3, 4, and 5 (p < 0.05, p < 0.01, p < 0.001), while 
at high dose (40 mg/kg) caused a significant decrease in the time latency 
on days 2, 3, 4, and 5 (p < 0.01, p < 0.001), whereas the galanthamine 
(8 mg/kg) caused a significant decrease in the latency time on days 1 to 
5 as compared to the 5xFAD-group (p < 0.05, p < 0.01, p < 0.001). The 
2NCP showed significant effects on the escape latencies [time= (F (4, 
150) = 17.9, p < 0.0001), treatment= (F (5, 150) = 69, P < 0.0001), 
interaction= (F (20, 150) = 1.05, p < 0.4104)] and SAB (F (5, 48) =
31.1, p < 0.0001 (Fig. 3.C & D). 
Fig. 2. Effect of the 2-(hydroxy-(2-nitrophenyl)methyl)cyclopentanone (2NCP) on; time latency to enter the dark box from light box (A) and the percent time spent in 
the light chamber (B) in the light/dark box test,balance and motor coordination in the balance beam test (C) and rotarod test (D). Data were analyzed with one-way 
ANOVA followed by Dunnett post hoc test (n = 10 mice/group). 
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Fig. 3. The effect of 2-(hydroxy-(2-nitro-
phenyl)methyl)cyclopentanone (2NCP) on; 
memory in elevated plus maze (A),short- and 
long- term memory in novel object recogni-
tion test(B), spatial memory and SAB in the 
Y-Maze test (C & D).The EPM, NOR, and SAB 
data were analyzed by one-way ANOVA fol-
lowed by Tukey’s post hoc test. The latency 
time data of Y-Maze were analyzed with two- 
way ANOVA followed by Bonferroni test. 
Bars represent mean ± SEM. *p < 0.05, **p 
< 0.01, ***p < 0.001 compared to the 
5xFAD-group and ###p < 0.001 compared 
to the WT group.   
Fig. 4. The effect of 2-(hydroxy-(2-nitrophenyl)methyl)cyclopentanone (2NCP) on escape latency time (A),time in the target quadrant (B), and number of the target 
quadrant crossings (C) in the MWM test. Data of “time in the target quadrant” and “number of the target quadrant crossings” were analyzed with one-way ANOVA 
followed by Dunnett post hoc test and data of escape latency time were analyzed with two-way ANOVA followed by Bonferroni test (n = 10 mice/group) *p < 0.05, 
**p < 0.01, ***p < 0.001 compared to the 5xFAD-group and ###p < 0.001 compared to the WT group. 
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3.2.7. Effect of 2NCP in the Morris water maze (MWM) test 
Morris water maze test is commonly used for the evaluation of hip-
pocampus dependant memory and learning in rodents [56].In the MWM 
test, the escape latency time was noted for each group of animals. The 
results revealed that the 5xFAD mice showed an increase in latency time 
as compared to the WT-mice (p < 0.001). The 2NCP at dose of 10 mg/kg 
shows a significant decrease in the latency time on the day 5 (p < 0.05), 
at a dose of 20 mg/kg exhibited a significant decrease in the latency on 
days 4 and 5 (p < 0.01, p < 0.001), while the 2NCP at high dose (40 mg/ 
kg) and galanthamine (8 mg/kg) caused a significant decrease in the 
latency time on days 3, 4, and 5 as compared to the 5xFAD-group (p < 
0.05, p < 0.001). Treatment with the 2NCP and galanthamine showed a 
significant effect on the escape latency [time= (F (4, 90) = 48.8, p < 
0.0001), treatment= (F (5, 90) = 33.1, P < 0.0001), interaction= (F (20, 
90) = 1.15, p < 0.3203)]. In the probe trials, the 5xFAD mice treated 
with the vehicle spent less time in the target quadrant and exhibited less 
number of crossings over the platform place in the target quadrant, 
while the 2NCP-treated 5xFAD mice showed a reciprocal behavior to the 
5xFAD mice treated with the vehicle (p < 0.05, p < 0.01, p < 0.001) 
(Fig. 4). 
3.3. Ex vivo assays 
3.3.1. Effect of 2NCP on the cortical and hippocampal AChE, BChE 
activities 
The effects of the 2NCP and galanthamine on percent enzymatic 
activities of AChE in the hippocampus (HC) (F (5, 12) = 20.8, p <
0.0001) and in the frontal cortex (FC) (F (5, 12) = 51.9, p < 0.0001) is 
shown in Fig. 5A, while the significant changes produce by the gal-
anthamine and 2NCP in the percent BChE activities in the hippocampus 
(HC) (F (5, 12) = 21.3, p < 0.0001) and in frontal cortex (FC) (F (5, 12) 
= 32, p < 0.0001) of the brain is shown in Fig. 5B. The 5xFAD mice 
exhibited a significant increase in the AChE and BChE activities in the 
HC and FC regions of the brain (p < 0.001). In both HC and FC, a 
significant decline in the AChE and BChEactivities has occurred with 
galanthamine and 2NCP treatment as compared to the 5xFAD animals 
(p < 0.05, p < 0.01, p < 0.001). The 2NCP at doses of 10, 20, and 40 
mg/kg and galanthamine causes a significant reduction in the AChE and 
BChE activities in the HC and FC (p < 0.05, p < 0.01, p < 0.001). 
3.3.2. Effects of 2NCP the cortical and hippocampal GST, GSH, and 
catalase activities 
The brain levels of glutathione-S-transferase (GST), glutathione 
(GSH), and catalase decrease in oxidative stress associated with AD [57]. 
The activities and level of antioxidants;GST, GSH, and catalase reduced 
significantly in the HC and FC of the 5xFAD mice as compared to the WT- 
mice. Treatment with the 2NCP enhances the percent activity of GST in 
the HC (F (5, 12) = 29.3, p < 0.0001 and FC (F (5, 12) = 20.1, p < 
0.0001. The 2NCP at doses of 10, 20, and 40 mg/kg showed an increase 
in the percent-activity of GST in both HC and FC (p < 0.05, p < 0.01, p 
< 0.001). The 2NCP treated groups showed an increase in GSH level in 
the HC (F (5, 12) = 19.1, p < 0.0001 and FC (F (5, 12) = 13, p < 0.0001. 
The 2NCP at doses of 20 and 40 mg/kg showed an increase in GSH level 
(%) in both HC and FC (p < 0.01, p < 0.001). The effect of 2NCP on 
percent catalase activity in the HC (F (5, 12) = 15.5, p < 0.0001 and FC 
(F (5, 12) = 100, p < 0.0001. The 2NCP at specified doses showed an 
increase in catalase activity (%) in both HC and FC (p < 0.05, p < 0.01, 
p < 0.001) (Fig. 5.C, D, E). 
3.3.3. Effect of 2NCP the cortical and hippocampal DPPH scavenging 
activity 
The level of antioxidant proteins in the HC (F (5, 12) = 29.8, p < 
0.0001) and FC (F (5, 12) = 25.2, p < 0.0001) is shown in Fig. 5.F. 
Homogenates from the brain of the 5xFAD mice showed a significant 
decrease in the percent scavenging activity in the HC and FC as 
compared to the WT-mice (p < 0.001), while the galanthamine and 
2NCP treated animals exhibited a significant increase in percent scav-
enging activity in both areas (Fig. 5.F). 
Fig. 5. Effect of the 2-(hydroxy-(2-nitrophenyl)methyl)cyclopentanone (2NCP) on the level/activity of AChE(A), BChE(B), GST (C), GSH (D), catalase (E), and DPPH 
percent scavenging activities of proteins (F)in the HC and FC. Through one way ANOVA followed by Tukey’s post hoc test data were analyzed. Bars represent mean 
± SEM. **p < 0.01, ***p < 0.001 compared to the 5xFAD-group, ###p < 0.001 compared to the WT-group. 
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3.4. RT-PCR studies 
3.4.1. Effect of 2NCP pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) in 
the HC and FC 
Inflammation has been involved in AD pathogenesis. The inter-
leukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor (TNF-α) 
are vital pro-inflammatory factors, play an important role in the chronic 
neuroinflammatory processes in AD,and high levels of these cytokines 
may be strong indicators for the AD progression [58].To find out the 
neuro anti-inflammatory effects of the 2NCP, the expression of various 
cytokines was evaluated using RT-PCR. The 5xFAD mice exhibited an 
increased mRNA level of IL-1β, IL-6, and TNF-α as compared to the WT 
mice. After the treatment of the 2NCP and galanthamine, the mRNA 
level of these cytokines was significantly reduced as compared to the 
5xFAD group (p < 0.01, p < 0.001) (Fig. 6). 
3.4.2. Effect of 2NCP on anti-oxidant response elements in the HC and FC 
Activation of nuclear factor erythroid 2-related factor (Nrf2) protects 
human bodies from deleterious stress by up-regulating anti-oxidative 
defense-pathway and inhibiting inflammation. It is reported that Nrf2- 
activators have therapeutic potential in AD-animal models [59]. The 
level of Nrf2 reduced in the hippocampus and frontal cortex of the 
5xFAD mice, while the 5xFAD mice treated with the 2NCP significantly 
enhance the mRNA level of Nrf2 (p < 0.001) (Fig. 6.E & I) 
3.5. Computational studies 
3.5.1. Computational study with cholinesterases 
The molecular study was performed to rationalize the binding 
mechanism of 2NCP with cholinesterases. Many studies have described 
the role of acetylcholinesterase (AChE) and butyrylcholinesterase 
(BChE) in the underlying mechanism of AD [60]. There-
foreAChEandBChEwere selected as biological targets for the docking of 
Fig. 6. The effect of 2-(hydroxy-(2-nitro-
phenyl)methyl)cyclopentanone (2NCP) on 
mRNA expression of IL-1β, IL-6, TNF-α, and 
Nrf2 was confirmed by RT-PCR (A).The ef-
fects of the 2NCP on the mRNA level of IL-1β 
(B&F), IL-6 (C&G), TNF-α (D&H), and Nrf2 
(E&I)in the HC and FC of transgenic mice. 
The results are shown in relative arbitrary 
unit (A.U). Each group containing four ani-
mals and bars represent mean expression in 
A.U ± SEM. The datawere analyzed with 
one-way ANOVA followed by Dunnett post 
hoc test.**p < 0.01, ***p < 0.001 compared 
to the 5xFAD-group and ###p < 0.001 
compared to the WT-group.   
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2NCP. When the 2NCP docked at the binding site of AChE, and the 
Glu199 groups of 2NCP mediated hydrogen bonds with the Tyr 130 of 
AChE. The bond length was 2.4 Å and the bond-energy − 9.42 Kcal/mol. 
The docked orientation of the 2NCP at the BChE binding site 
revealed that inhibitor binds nicely within the binding groove and the 
–OH group of the 2NCP formed strong hydrogen bond with the BChE 
through Arg 242 at a distance of 2.88 Å. The docking score of the 2NCP 
was highly negative (-10.51) at the ligand binding site of BChE. The 
findings of the docking study show that the AChEandBChEcould be po-
tential targets for the 2NCP. The docked orientation of the 2NCP is 
presented in the Fig. 7. 
3.5.2. Computational study withNF-κB 
Using the KEGG pathway,it was deduced that NF-κB regulates the 
production and expression of different cytokines including TNF, IL-1, IL- 
6, iNOS, COX2, and M− CSF. Since the 2NCP reduced the mRNA levels of 
the inflammatory mediators (IL-1β, IL-6, TNF-α), therefore, it may bind 
with NF-κB to exhibit its activity. The binding of the 2NCP with NF- 
κBwas confirmed by molecular docking studies. The homodimer of NF- 
κB (p50 subunit) binds with DNA, where several residues including 
Arg54, Arg56, Tyr57, Cys59, Glu60, Lys144, Gln274 and Gln306 of 
Chain A, and Arg54, Glu60, Pro62, Lys144, Gln274, Arg305 and Gln306 
of Chain B are involved in protein-DNA complex formation. The binding 
residues are shown in Fig. 8.A. The compound 2NCP was targeted at 
both chains. The 2NCP showed excellent binding interactions at the 
binding hotspot of Chain B, where the compound was stabilized by the 
hydrogen bonding with the side chains of Thr143 and Lys145. The –OH 
group of the 2NCP donated H-bond to the side chain of Thr143 at a 
distance of 2.04 Å, while the nitro group of the 2NCP accepted H-bond 
from the side chain of Lys145 with the bond length of 2.21 Å. The 
docking score of the 2NCP was − 5.51 Kcal/mol. The good binding in-
teractions and high docking score suggest that the 2NCP has a binding 
potential with NF-κB. The binding mode of the 2NCP is shown in Fig. 8. 
B. 
4. Discussion 
Chronic neuroinflammation and oxidative stress serve a key role in 
Alzheimer’s disease (AD). According to the cholinergic hypothesis, 
memory impairment in AD patients also linked with the deficit in 
cholinergic function of the brain. Although there are five drugs approved 
by the FDA for the treatment of AD, these drugs provide symptomatic 
relief to patients not cure the cause of AD [61–62]. Evidence suggests 
that neuroinflammation suppression is considered a fascinating thera-
peutic entity to halt the development of AD [63]. 
Decrease level of acetylcholine (ACh) is responsible for cognitive 
impairment in AD. Acetylcholinesterase (AChE) hydrolyzes ACh thus 
terminate the cholinergic-transmission. Therefore, AChE inhibition is 
supposed to compensate for the reduced ACh level in the brain [64]. In 
this study, the anti-cholinesterase potential of the 2NCP was assessed in 
the in vitro and ex vivo studies. The 2NCP produced beneficial effects 
similar in intensity to that produced by standard, galanthamine. Gal-
anthamine inhibits the acetylcholinesterase enzyme reversibly and 
competitively, effective for the symptomatic treatment of AD [65]. The 
in vitro anti-cholinesterase assay revealed that the 2NCP has concen-
tration dependantAChE and BChE inhibition properties. The IC50 values 
were determined against AChE and BChEenzymes which were 17 and 
23μ g/ml respectively. The 2NCP caused significant inhibition of percent 
activities of AChE and BChE in the HC and FC tissues of the 5xFAD mice. 
Therefore due to the inhibition of the AChE and BChE, the level of 
Fig. 7. 2D and 3D docked view of 2NCP in a pocket of AChE (A) and BChE enzymes (B).  
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acetylcholine in the synaptic cleft maintained for a long time, which 
stimulates cholinergic receptors. The augmented cholinergic conduction 
by the 2NCP shows their usefulness in memory restoration in AD. 
Oxidative stress plays an important role in the pathogenesis of AD. It 
has been reported that the increased level of Aβ1-40 and Aβ1-42 is 
associated with an elevated level of oxidative stress products generated 
from different organic substances in the cortex and hippocampus of AD 
individual, while brain regions such as the cerebellum having a low level 
of Aβ due to fewer concentrations of oxidative stress markers [7,66]. 
Antioxidants such as catalase, glutathione (GSH), and glutathione-S- 
transferase (GST) play an important role in preventing or reducing the 
progression of oxidative stress-mediated by free radicals [67–69]. GSH 
level, GST and catalase activities decreased in AD and mild cognitive 
impairment as compared to the normal brain [70–72]. Nrf2 plays a key 
role in the cellular redox system regulation; protects many CNS cell 
types from ROS. Susceptibility to oxidative stress increased by 
decreasing Nrf2 levels. Expression of Nrf2 in the AD brain decreases 
significantly as compared to the normal brain and their activity reduced 
in the hippocampal and frontal cortex neurons, over expression of the 
Nrf2 in the HC and FC improves spatial learning and memory [73]. 
Molecule with the active antioxidant potential is used to scavenge such 
harmful radicals [19]. The 2NCP has promising antioxidant potential, 
since it scavenged DPPH free radicals, considerably improved the ac-
tivities of GST and catalase, and enhanced the level of GSH and Nrf2 in 
the HC and FC of transgenic 5xFAD mice. 
Neuroinflammation has a vital role in causing cognitive impairment 
and neurodegenerative disorders, it occurs around the Aβ plaques, 
characterized by elevated levels of free radicals, pro-inflammatory cy-
tokines, and activation of astro- and microglia [74–75]. Pro- 
inflammatory cytokines such as IL-1β, IL-6, and TNF-α are up- 
regulated in the brain of AD patients and transgenic 5xFAD mice 
[76–81]. In RT-PCR study it is shown that the 2NCP reduced the level of 
these pro-inflammatory cytokines in the HC and FC of the transgenic 
mice, specifically the 2NCP caused more reduction in the TNF-α level 
than galanthamine. 
NF-κB signaling plays an important role in gene regulation and is 
implicated in inflammation, oxidative stress, and apoptosis. The level of 
NF-κBis significantly increased in the brain of AD patients. The elevated 
level of NF-κBis caused by the increase ROS production. NF-κB in turn 
increases the expression of several cytokines including iNOS, COX2, 
TNF-α, IL-1, IL-6, and M− CSF. These cytokines subsequently reduce the 
long-term potentiating in AD patients [82]. Thus, the compound 2NCP 
was docked at the binding cavities of NF-κB which revealed that the 
2NCP is well accommodated in the DNA binding site of NF-κB with high 
binding energy. The docking scores and binding interactions suggest 
that the 2NCP reduces the level of TNF-α, IL-1β, and IL-6 by targeting the 
NF-κB. 
The light/dark box, balance beam, rotarod, EPM, NOR, paddling Y- 
maze, and MWM tests were performed for determining the effect of the 
2NCP on the behavior of the 5xFAD mice in terms of anxiety, balance, 
motor coordination, hippocampal-dependent spatial learning and 
memory, respectively [27–28]. 
The light/dark box test was performed for the assessment of anxiety. 
The time latency to enter the dark compartment and the time spent in 
Fig. 8. (A) The 3D-structure of homo-
dimer NF-κB in complex with dsDNA is 
shown. The chain A and B of homodimer 
are presented in green and red ribbons. 
The double strands of DNA are shown in 
the blue and cyan ribbon models. The 
binding residues of chains A and B are 
also highlighted in green and red stick 
models in their respective chains. The 
hydrogen bonds between DNA and the 
binding residues of NF-κBare depicted in 
black lines.(B) The binding mode of the 
2-(hydroxy-(2-nitrophenyl)methyl) 
cyclopetanone (2NCP) in the binding 
cavity of chain B of NF-κB is shown in 
figure. The protein–ligand interactions 
are highlighted in the box. The ligand 
(2NCP) is presented in the green ball 
and stick model, while binding residues 
are shown in the red stick model, while 
H-bonds are shown in black lines.   
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the light compartment were noted in this test. No significant differences 
were observed among all groups, indicates that the 2NCP did not cause 
anxiety. 
The balance beam and rotarod assays have been an effective tool in 
measuring balance and motor coordination [83]. The number of vari-
ables can be recorded from the balance beam and rotarodtests for the 
assessment of balance (time spent on balance beam instrument) and 
coordination (latency time to fall from the rod). Mice were tested on the 
balance beam and rotarod, the results showed no significant difference 
in time duration on the balance beam and latency times of falling among 
all groups of animals implying that the 2NCP did not cause any balance 
and motor deficits. 
Elevated plus maze (EPM) test is used for the assessment of anxiety, 
spatial learning and memory in mice [84–85]. Reduce latency time (TL) 
in the EPM task indicated the improvement in memory and learning, 
while increase TL indicates memory impairment [86]. The results of the 
EPM test showed that the 2NCP decreased the TL in the retention phase 
indicate improved memory. 
The novel object recognition (NOR) test was used for the assessment 
of short- and long term memory [87]. The 5xFAD mice treated with 
vehicle exhibited cognitive deficits indicated by decreased discrimina-
tion index, while the 2NCP reversed the cognitive deficits presented by 
the transgenic 5xFAD mice in the NOR test paradigm. 
In the paddling Y-Maze test, the escape latency time was recorded for 
five days consecutively. The 5xFAD mice treated with the vehicle dis-
played low memory indicated by high escape latency times. The 2NCP 
(40 mg/kg) exhibited a significant improvement in memory on days 2, 3, 
4, and 5 in comparison with other groups, while the 2NCP at the dose of 
20 mg/kg has a significant effect on memory on days 3, 4, and 5. The 
5xFAD mice treated with the 2NCP (10 mg/kg) exhibited a decrease in 
the escape latency on days 4 and 5. Spontaneous alternation behavior 
(SAB) of the animals was observed on day 5 and expressed as percent 
activity. A high level of SAB shows less memory impairment and better 
cognitive function, while the decrease level of SAB indicates less 
working memory [88]. 
The Morris water maze (MWM) task is used for the assessment of 
spatial learning and memory in rodents; also it can be used to investigate 
the damage to particular cortical regions of the brain [89]. In the MWM 
task, during training trials spatial information acquisition was assessed, 
while in probe trials memory retention was determined. The 5xFAD 
mice exhibited memory impairment and require more time to find the 
platform as compared to the WT-mice in training trials. While in the 
probe trial, these transgenic mice exhibited a significant decline in the 
time spent in the target quadrant and number of crossings over target 
quadrant. The 5xFAD mice treated with the 2NCP displayed a significant 
decrease in the latency time during training trials, more time in the 
target quadrant and frequent crossing over the target quadrant during 
probe trials as compared to the 5xFAD mice treated with the vehicle. 
5. Conclusion 
In conclusion, the current study revealed that the 2NCP has signifi-
cant antioxidant, anticholinesterases, anti-neuroinflammatory and 
attenuative potential against memory impaiment in the 5xFAD trans-
genic mice. The beneficial effects of 2NCP appear to occur through 
various mechanisms; including the scavenging of the DPPH free radicals, 
inhibition of the AChE, BChE, and NF-κB, inhibition of induction of 
cytokines (IL-1β, IL-6, TNF-α) and Nrf2. 2NCP is useful because of lack of 
motor coordination deficit. Hence, our findings suggest that the 2NCP 
might be a multi-targeted drug for the treatment of AD. However, more 
comprehensive studies are required to explore the detailed mechanistic 
role of the 2NCP against the Alzheimer’s disease. 
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